Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient

Despite the development of new therapies in the last few years, metastatic prostate cancer (PCa) is still a lethal disease. Radium-223 (Ra-223) is approved for patients with advanced castration-resistant prostate cancer (CRPC) with bone metastases and no visceral disease. However, patients’ outcomes...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Francesca Zacchi, Joan Carles, Macarena Gonzalez, Xavier Maldonado, Raquel Perez-Lopez, Maria Eugenia Semidey, Joaquin Mateo
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2024-03-01
Edice:	Frontiers in Oncology
Témata:	Radium-223 bone response bone metastases metastatic castration-resistant prostate cancer prognosis
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1331643/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!